全文获取类型
收费全文 | 1717801篇 |
免费 | 129029篇 |
国内免费 | 5963篇 |
专业分类
耳鼻咽喉 | 21924篇 |
儿科学 | 55881篇 |
妇产科学 | 46443篇 |
基础医学 | 244594篇 |
口腔科学 | 49186篇 |
临床医学 | 154824篇 |
内科学 | 337240篇 |
皮肤病学 | 38873篇 |
神经病学 | 132429篇 |
特种医学 | 64815篇 |
外国民族医学 | 263篇 |
外科学 | 259896篇 |
综合类 | 43232篇 |
现状与发展 | 13篇 |
一般理论 | 535篇 |
预防医学 | 125677篇 |
眼科学 | 40839篇 |
药学 | 126303篇 |
37篇 | |
中国医学 | 5921篇 |
肿瘤学 | 103868篇 |
出版年
2021年 | 14363篇 |
2019年 | 14451篇 |
2018年 | 20966篇 |
2017年 | 16085篇 |
2016年 | 17441篇 |
2015年 | 20275篇 |
2014年 | 27844篇 |
2013年 | 39221篇 |
2012年 | 54648篇 |
2011年 | 57583篇 |
2010年 | 34084篇 |
2009年 | 31720篇 |
2008年 | 52845篇 |
2007年 | 56206篇 |
2006年 | 56585篇 |
2005年 | 53998篇 |
2004年 | 51589篇 |
2003年 | 48908篇 |
2002年 | 47066篇 |
2001年 | 92306篇 |
2000年 | 94136篇 |
1999年 | 77564篇 |
1998年 | 20188篇 |
1997年 | 17720篇 |
1996年 | 17777篇 |
1995年 | 17087篇 |
1994年 | 15563篇 |
1993年 | 14230篇 |
1992年 | 57568篇 |
1991年 | 55406篇 |
1990年 | 53088篇 |
1989年 | 50858篇 |
1988年 | 46265篇 |
1987年 | 45020篇 |
1986年 | 42302篇 |
1985年 | 40042篇 |
1984年 | 29381篇 |
1983年 | 24933篇 |
1982年 | 13913篇 |
1979年 | 25544篇 |
1978年 | 17578篇 |
1977年 | 14907篇 |
1976年 | 13875篇 |
1975年 | 14565篇 |
1974年 | 17631篇 |
1973年 | 16945篇 |
1972年 | 15673篇 |
1971年 | 14455篇 |
1970年 | 13431篇 |
1969年 | 12517篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献
12.
13.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
14.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
15.
16.
Clinical & Experimental Metastasis - 相似文献
17.
18.
19.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献
20.